Get the Daily Brief
Latest Biotech News
Boston Scientific expands pelvic health with Valencia buy; deal values hit records
Boston Scientific agreed to acquire Valencia Technologies to add the implantable tibial nerve stimulation (eCoin) system to its pelvic‑health portfolio, citing complementary product fit and a move...
New molecular insights in Parkinson’s: cuproptosis genes and microglial FcγR
Two independent studies exposed converging mechanisms implicated in Parkinson’s disease. A multi‑omics analysis linked cuproptosis‑related genes to PD pathogenesis, identifying copper‑dependent...
ImmunityBio CAR‑NK posts durable complete responses in Waldenström’s
ImmunityBio reported durable complete responses in an early trial of its off‑the‑shelf CD19 CAR‑NK therapy for Waldenström’s macroglobulinemia. The Phase 1 QUILT‑106 study enrolled relapsed...
Boston Scientific to buy Penumbra for $14.5B – vascular push
Boston Scientific announced a definitive agreement to acquire Penumbra for about $14.5 billion, aiming to expand into thrombectomy and embolization markets. The transaction brings Penumbra’s...
ARPA‑H backs UC San Diego to 3D‑print patient‑specific human livers
UC San Diego received up to $25.8 million from ARPA‑H to develop patient‑specific, 3D‑bioprinted livers under the PRINT program, funding a five‑year effort to create transplantable,...
Tecvayli cuts death or progression risk sharply in early multiple myeloma
Johnson & Johnson reported Phase 3 results showing Tecvayli reduced the risk of disease progression or death by a substantial margin in patients with early relapsed multiple myeloma. The...
GLP‑1 class splits outcomes — Alzheimer’s trial fails; tirzepatide resolves MASH
Two high‑profile clinical developments this week delivered mixed news for enteroendocrine therapeutics. A large Alzheimer’s trial testing GLP‑1 drugs failed to meet endpoints, reporting no...
MRD market crystallizes: Veracyte launches TrueMRD; BloodPAC issues validation protocols
Veracyte detailed plans to launch TrueMRD for muscle‑invasive bladder cancer and expand its whole‑transcriptome sequencing capabilities while targeting reimbursement pathways and guideline...
Novo Nordisk Foundation pledges up to $850M to scale European biotech
The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s support for startups across Europe, moving the Danish‑born innovation engine into a continental...
Conference cash flow: JPM lifts biotech financings and deal activity
Industry trackers reported a notable uptick in biotech financings and deal volume during JP Morgan week, with BioCentury flagging increased capital commitments and Q4 2025 closing the year with a...
Vedanta cuts staff to prioritize phase‑3 VE303 for C. difficile
Vedanta Biosciences said it significantly reduced its workforce and refocused resources on advancing VE303, an eight‑strain live bacterial consortium in Phase 3 for prevention of recurrent...
HHS greenlights controversial newborn hepatitis B trial in Africa — ethics debate continues
The U.S. Department of Health and Human Services confirmed a planned randomized study in Guinea‑Bissau that will investigate health effects of neonatal hepatitis B vaccination, despite ethical...
ImmunityBio’s off‑the‑shelf CAR‑NK: durable complete responses in Waldenström’s
ImmunityBio reported early clinical activity for its allogeneic CD19 CAR‑NK therapy in patients with Waldenström’s macroglobulinemia. Company data show durable complete responses in the first four...
Tecvayli tops standard regimens – J&J cites survival gains in earlier multiple myeloma
Johnson & Johnson disclosed Phase 3 results showing Tecvayli (a bispecific antibody) reduced the risk of progression or death by 71% versus standard regimens in earlier‑line multiple myeloma...
UC San Diego wins ARPA‑H grant: $25.8M to 3D‑print patient‑specific livers
UC San Diego secured up to $25,771,771 from ARPA‑H to develop a patient‑specific, 3D‑bioprinted human liver under the agency’s PRINT program. The five‑year award funds multidisciplinary work to...
MRD moves: BloodPAC issues validation protocols as Veracyte primes TrueMRD launch
BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays to harmonize MRD (minimal residual disease) testing standards across platforms....
Novo Nordisk Foundation pledges up to $850M to seed European life‑science startups
The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s reach across Europe, the foundation said. The funding will scale startup support services that the...
White House pushes ‘Great Healthcare Plan’ — drug‑pricing fight shifts to Congress
The administration unveiled the Great Healthcare Plan promising lower drug costs and direct payments to ACA enrollees, but industry executives told reporters the policy lacks operational detail....
Vedanta trims workforce to concentrate resources on VE303 phase‑3 for C. difficile
Vedanta Biosciences confirmed a significant headcount reduction to preserve capital and focus on advancing VE303, its eight‑strain live bacterial consortium for preventing recurrent Clostridioides...
FDA grants RMAT to iRegene’s NouvNeu001 — regulatory double‑play for iPSC Parkinson’s therapy
iRegene Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to NouvNeu001, its chemically induced allogeneic iPSC‑derived cell therapy for...